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Chronic back and neck pain is a prevalent disability, often caused by degeneration of the inter-
vertebral disc. Because current treatments for this condition are less than satisfactory, a great
deal of effort is being applied to develop new solutions, including regenerative strategies. How-
ever, the path from initial promising idea to clinical use is fraught with many hurdles to over-
come. Many of the keys to success are not necessarily linked to science or innovation.
Successful translation to clinic will also rely on planning and awareness of the hurdles. It will be
essential to plan your entire path to clinic from the outset and to do this with a multidisciplinary
team. Take advice early on regulatory aspects and focus on generating the proof required to sat-
isfy regulatory approval. Scientific demonstration and societal benefits are important, but trans-
lation cannot occur without involving commercial parties, which are instrumental to support
expensive clinical trials. This will only be possible when intellectual property can be protected
sufficiently to support a business model. In this manner, commercial, societal, medical, and scien-
tific partners can work together to ultimately improve patient health. Based on literature sur-
veys and experiences of the co-authors, this opinion paper presents this pathway, highlights the
most prominent issues and hopefully will aid in your own translational endeavors.
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1 | DESIGNING FOR SUCCESS
When developing new regenerative therapies for the degenerated
intervertebral disc (IVD), a major cause of back and neck pain, it is
essential to involve multidisciplinary teams from concept, through
translation from bench to bedside, and even clinical application. The
involvement of end users, including clinicians and patient groups, in
the early stage of development is important to ensure that developed
therapies will be applicable in the clinic and address an area of unmet
need. End user engagement is also often required when applying forAbbey Thorpe and Frances C. Bach contributed equally to this study.
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ethical permission for use of human tissues and clinical trial applica-
tions.1 Furthermore, engagement with end users is often required dur-
ing design of research phases for funding, especially within Europe.
The (regulatory) pathway to clinic is also important to consider from
the outset, attention to appropriate laboratory tests to demonstrate
proof of concept and initial toxicity and animal testing. Early consider-
ations of commercialization, patenting and regulatory approvals are
necessary to reduce delays to clinical trials and pathways to the clinic.
Throughout laboratory and animal testing, good laboratory practice
(GLP) or similar is required to support findings, regulatory approvals
and patent applications. This includes aspects of good record keeping
to laboratory maintenance and quality control.2 The design of clinical
trials, stratification of patients and outcome measure design are all
important to ensure that the correct questions are addressed at the
appropriate time.
This review aims to map out the important aspects to consider
during the development of regenerative therapies for the IVD. Cover-
ing the developmental stages for a diverse range of regenerative
approaches including: gene, cell, biological factors, and biomaterial
approaches to repair and regenerate the IVD, as a potential treatment
for chronic back and neck pain.
2 | BENCH SIDE TESTING: IN VITRO AND
EX VIVO TESTING
The first stage in developing a new regenerative therapy for the IVD
is testing in vitro, often in mammalian cell culture. This stage is used
to perform initial proof of principle studies and fundamental cellular
toxicology (viability) studies on relevant cell types. Important aspects
to consider during the design of in vitro and ex vivo testing includes:
species, sources of cells and tissues, and culture conditions. The spe-
cific question being addressed and stage within the developmental
pathway will require different levels of complexity (Figure 1).
2.1 | Species and cell/tissue source
The choice of cell source is an important question. It is well known
that species-specific responses can be observed7,8 and as such, cau-
tion must be applied when using nonhuman cells in initial proof of
principle testing. These differences could arise from differential
species-dependent expression of proteins and receptors, cell types
isolated from tissues (eg, notochordal cells), or the disease status of
the tissues.9–11 In view of the challenges in accessing human cells, the
majority of animal cells utilized in initial experimental studies are from
normal young adult animals, which do not represent the cellular phe-
notype seen within the degenerated (human) IVD, which are senes-
cent and exhibit a catabolic phenotype which has implications on
regenerative therapies.12–14 Over the last 10 years, there has been
increased research on human cell sources with approximately 50% of
studies culturing IVD cells or cells for regeneration of the IVD sourced
from human (Figure 2A,C). Accessibility to human tissues is more com-
plex for tissue explant or organ culture studies with the majority of
these utilizing animal tissues (Figure 2B), especially cow tails, due to
their ease of access and similarity in cell type and structure to human
discs.15 Similarities between animal and human disc tissues have been
reviewed elsewhere.15 The utilization of animal tissues can be useful
for initial tests and studies have attempted to mimic the degenerate
disc within such systems (see below). However, no animal tissue rep-
resents the human situation directly. Therefore, human tissues should
be utilized wherever possible, which also enables patient variation to
be determined. Prior to translation to animal testing, it is also essential
to confirm results in vitro within the species of choice for in vivo
experimentation to ensure these cell types respond in the same way
as human cells prior to animal model selection, as indicated recently,
for example, by species-specific responses to Link-N.8
2.2 | Culture systems
Two-dimensional (monolayer) culture of nucleus pulposus (NP) cells is
well known to lead to changes in cellular phenotype, characterized by
rapid de-differentiation within the first passage, for example, loss of
normal matrix synthesis (collagen type II and aggrecan) and gain of
collagen type I.14,16 Moreover, it acts as an oversimplification of the
cellular environment, lacking cell-extracellular matrix (ECM) interac-
tions. Two-dimensional (2D) culture systems for IVD studies are
widely used (Figure 3A). While 2D culture has its use, particularly in
initial cellular toxicology studies and preliminary proof of concept
studies, it is difficult to translate results from 2D culture directly to
the in vivo environment. Three-dimensional culture systems such as
pellet17 or alginate14 have been shown to restore the phenotype (with
appropriate expression of IVD matrix molecules) of native NP cells
and collagen scaffolds for annulus fibrosus (AF),18 thus, are a useful
model to study effects of gene therapy and biological factors. How-
ever, these systems are often limited to single cell types and with the
exception of newly deposited matrix do not recapitulate the complex-
ity of cellular and extracellular matrix components and interactions
FIGURE 1 Recommended culture systems for developmental stages
in regenerative therapy developments for the intervertebral disc
(IVD). Regulatory classifications are shown in italics. ATMP, Advanced
Therapeutic Medical Product. Images are representative images of
culture systems: 2D culture: IVD cells in monolayer; 3D culture: IVD
cells in alginate culture; tissue explants: explant culture systems;
organ culture: examples of organ culture systems3–6
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thereof, which exist in vivo. The IVD regeneration field would benefit
from defining a standard culture system such as alginate for NP and
collagen for AF cells and its conditions (Table 1) that would be used
worldwide and as such enable comparison of efficacy results. How-
ever, the defined “gold standard” will still need adjustments depending
on the clinical questions addressed, as conditions in the IVD differ
depending on age, spinal level, health state and underlying disease
process.
Until early in the 21st century, culture of IVD tissue explants,
especially NP tissue explants, were hampered by tissue swelling, loss
of extracellular matrix, cellular phenotype and viability. However, a
number of culture systems are now available which can maintain tis-
sue explants of animal and human tissue in culture for prolonged
periods of time. These systems either constrain tissue volume,3,27,28
culture tissue in raised osmotic pressures,29 or under compressive
loading,30 which prevents tissue swelling, maintains tissue architec-
ture and cellular phenotype. These systems are particularly useful as
human tissue obtained from surgery can be utilized as small pieces of
intact tissue and can be maintained in culture. Such systems have
been employed to excellent effect to study proof of principle studies
on regenerative approaches including biological,31,32 cellular33–35, and
injectable hydrogel systems.36 These studies can provide useful initial
data on local tissue responses, integration and delivery to tissues,
which are essential in the pathway to clinic.
However, NP explants fail to model the interactions of different
cell types within the disc and nutritional diffusion. Although this can
be simulated to a certain extent by adjusting the nutrient supply in
the media, this does not mimic the gradient seen in a whole IVD. Thus,
a number of organ culture bioreactors have been developed which
can maintain whole discs: mainly mouse, rabbit, sheep, cow, and goat
discs. Recently, a long-term IVD organ culture model that retains the
vertebral bone system was developed.6 This model is useful for test-
ing potential drugs on disc repair37 and is based on the bovine IVD. To
study repair, IVDs are maintained in organ culture and degradation is
induced by injection with trypsin. The whole organ culture system
used for the bovine work is to some extent applicable to human IVDs,
but in this case degeneration is not truly reflective of the human IVD.
A number of systems have recently been developed which can main-
tain whole cadaveric human discs, which can allow investigations in
naturally degenerate tissues.38–40 These systems have been reviewed
in a number of excellent reviews.41,42
2.3 | Culture conditions
The native IVD in vivo is a hostile environment, characterized by low
oxygen tension, low nutrition, high osmolality, low pH and exists under
dynamic load43,44 (Table 1). Yet the majority of in vitro studies are per-
formed in nutrient-rich culture media, most commonly Dulbecco's
FIGURE 2 Utilization of cells and tissues for in vitro studies on intervertebral disc pathology and regeneration from 2008 to 2017. Results
generated from a literature search for papers published over the last 10 years for “intervertebral disc culture.” (A) Species utilized for studies with
isolated cells, (B) species utilized for tissue explant and organ cultures, (C) overall utilization in in vitro studies during the period of 2008-2017
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Modified Eagle Medium (DMEM) or DMEM/F12 consisting of high glu-
cose concentrations, at neutral pH (7.4), low osmolality (~350 mOsm/
kg), and under static culture conditions at 21% O2. The NP experiences
mostly hydrostatic pressure, as high as 2.5 MPa, whereas the AF is under
complex loading leading to direction-dependent tensile, compression and
shear stresses. The magnitude, duration and frequency of tissue loading,
and deformation varies over a diurnal cycle.
Culture conditions are also essential to consider during expansion
of cells for biobanking of IVD cells for regenerative approaches.
Expansion conditions, including passage number, oxygen tension, sup-
plements, and osmolality have been shown to influence the cell phe-
notype and as such influence the regenerative capacity and
differentiation of mesenchymal stromal cells45 and NP cells.46 These
conditions can be tuned, either to achieve optimal regenerative
performance or to achieve an NP phenotype that resembles better
the NP cells present within a degenerative niche.
During testing of regenerative approaches, systems should be
tested within conditions which mimic the native IVD environment
(Table 1). However, key factors preventing many researchers from
modulating culture conditions are the comparison to previously pub-
lished data and facilities that are available. Some studies are indeed
starting to modulate these conditions within in vitro culture studies
(Figure 3B). A key feature, however, which currently hampers in vitro
culture modifications is accurate determination of actual levels seen
in vivo.47 Furthermore, these conditions are known to change during
degeneration, but levels will vary between patients and across regions
within the IVD, and these measures are very difficult to determine
in vivo and often depend on computer modeling to provide suggested
FIGURE 3 Culture conditions utilized from 2008 to 2017. Results generated from a literature search for papers published over the last 10 years
for “intervertebral disc culture.” (A) Culture environment utilized (2D vs 3D vs tissue), (B) percentage of studies which modulated environmental
conditions to mimic the intervertebral disc environment
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concentrations.44 However, in order to gain a more educated under-
standing of how potential regenerative therapies will behave within
the complex environment of the degenerated human IVD, in vitro and
ex vivo culture systems must evolve to recapitulate the conditions
seen within the degenerated IVD.
3 | MODELING THE DEGENERATIVE NICHE
IN VITRO
The degenerated IVD is a hostile environment for cells with further
decrease in nutrients and pH and altered osmolarity compared to nor-
mal discs, which was recently reviewed by Sakai and Anderson.43 The
degenerated niche also contains abundant catabolic cytokines, degra-
dative enzymes, matrix fragments increased levels of free calcium
(Ca2+),6 neurotrophic and angiogenic factors, which together could
alter the behavior of any proposed regenerative therapy.48 For thera-
pies which rely on the native cells of the IVD, these become
senescent,13 alter phenotype, and undergo apoptosis, which results in
an altered and/or reduced cell source available to respond to potential
gene and biological treatments.48 While newly implanted cell sources
may not survive and/or differentiate into the correct NP cell pheno-
type within the catabolic environment of the degenerate disc.49
Hence, it is important to assess any potential regenerative therapy
within an environment which mimics the degenerated niche as much
as possible (Table 1) prior to progression to clinical trials. ex vivo tissue
explant and organ culture systems have in part begun to re-create this
niche with various degrees of success. Methods to mimic the changes
observed in human IVD degeneration include enzymatic NP
digestion,50 surgical methods to create AF injury,51 and overloading
(by magnitude, duration, and frequency).52 However, these systems
can only replicate some morpho-histo-pathological and cellular
changes and it is unknown how closely they mimic/induce in vivo
degenerative mechanisms. To date, the best ex vivo model systems
available are those based on human degenerative IVD tissue/organs,
but even these do not fully recapitulate the full in vivo environment
as they are decoupled from systemic interactions, for example,
immune, nervous, and endocrine systems.
Efforts are underway to develop realistic computational models
for the human IVD, so called “virtual human IVD”, with the aim of
diagnosing and understanding IVD degeneration.53,54 As a step
between simplified in vitro culture experiments and more sophisti-
cated ex vivo culture employing tissue explants or even whole tissue
organs, in silico modeling could provide an avenue to further identify
essential environmental and cellular aspects that need to be consid-
ered in follow-up studies. Although the field is still in its infancy,55 this
may have the potential of performing in silico clinical trials and may
help to optimize and guide the rational design of therapeutic
interventions.56
4 | PRECLINICAL ANIMAL MODELS
When promising (regenerative) treatment candidates have been
established in vitro and/or in ex vivo tissue/organ cultures mimicking
the degenerative disc niche, the next step would be to test these can-
didates in clinically relevant animal models for safety and efficacy
prior to starting human clinical trials. To generate an overview of the
types of efficacy outcome measures previously used, a literature
search for papers published over the last 20 years on “regenerative
treatments for the IVD in animal models” was performed. A total of
112 papers were reviewed and the outcome measures appeared to
vary considerably between the different types of assessment (ie, his-
tological, macroscopic, radiological, biochemical, mechanical, and pain
assessment; Figure 4A,B). It is well known that IVD degeneration is a
complex disease with cellular and biochemical matrix changes.12,57,58
Therefore, the assessment of histological and biochemical outcome
measures is essential to fully evaluate the native cell response and
matrix regeneration capacity of any treatment strategy. Despite this,
histological, biochemical and/or radiological changes indicative of
degeneration can be found in patients in the absence of pain, demon-
strating that the two do not always correlate.59–61 Therefore, histo-
logical, biochemical and/or radiological improvements observed in
animal models may not necessarily translate clinically into a reduction
in disability and for this reason should not be used alone to indicate
therapeutic success.
From a clinical point of view, the ultimate aim of any treatment
developed for neck and back pain is to alleviate pain and restore the
biomechanical function of the IVD. Interestingly, from the 112 papers
reviewed, only 4% of these papers performed some kind of biome-
chanical assessment to determine the success of the therapy under
investigation, and to the authors knowledge none of the papers
reviewed had assessed pain as an outcome measure following admin-
istration of a regenerative therapy (Figure 4). This is likely due to the
fact that standardized methods to assess biomechanical function and
pain in animal models are less well defined. Furthermore, it is a com-
mon practice in translational studies to employ more than one levels
within in each animal in order to reduce the number of animals
needed in an experiment (3Rs principle: reduction, replacement,
refinement). This limits the ability to assess pain properly. As such,
once a promising treatment candidate has been encountered in
TABLE 1 Recommended culture conditions to mimic the normal and
degenerated intervertebral disc (IVD) environment
Normal
IVD Degenerate IVD
Oxygen tension (%)19,20 1-5 1-5
Glucose concentration
(nM/mm3)21
0.94-4 0.94-4
Osmolality (mOsm/kg)22 400-500 350
pH23,24 7.0-7.2 6.5-7.1
Loaded environment Dynamic
load
Dynamic load
Catabolic factors25,26 Cytokines (particularly IL-1;
100 pg/mL), Ca2+ (2.5-5 mM),
or use of naturally degenerate
cells/tissue within 3D culture,
explants and organ cultures
Note that for proper mimicking the degenerative environment in 3D
hydrogel culture low density of cells should be employed; for explant and
organ culture diffusion of oxygen and glucose into the disc should be con-
sidered and thus higher culture concentrations may be required to result
in these internal concentrations.
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studies with more than one spinal level injected with a different treat-
ment, it would be recommended to perform an in vivo study on this
treatment candidate injected at only one spinal level, enabling pain
assessment.
Suitable methods to assess pain in animal models is still in its
research infancy; for those that do exist, it is not clear whether these
methods will relate to human neck and back pain, since the source of
IVD-related pain in humans is not always defined.62,63 A number of
preclinical small animal models that mimic specific aspects that con-
tribute to low back pain (LBP) has been recently reviewed by Shi
et al.64 Pain measurements in large animal models are primarily quali-
tative65 and deduced from objective gait analysis that does not allow
for the exact (spinal) localization.66 Specifically in the case of dog
patients with chronic back pain employed as a model for humans
within the concept of “One Medicine,” owners can fill in question-
naires regarding pain assessment aspects and inherent impairment of
mobility as would humans entering a clinical trial.67 Despite the diffi-
culties, when evaluating the success of any potential therapy in animal
models, it is recommended that some measure of biomechanical func-
tion and pain assessment, appropriate to the selected animal model, is
performed. These outcome measures should be performed in combi-
nation with histological, biochemical and/or radiological outcome
measures to evaluate the native IVD cell response, including produc-
tion of catabolic/inflammatory factors, repair of matrix components
and restoration of disc height. All outcomes should ideally be deter-
mined blindly and objectively, for example, by using quantitative scor-
ing systems. This will improve knowledge concerning the efficacy of
the therapeutic and may improve the translation of clinical findings
within animal models to those found in humans. In this way, the
chance of failure of the treatment candidate in human clinical trails
would be reduced and translational success would be improved.
Commonly used experimental animal models for IVD degenera-
tion include mice, rats, rabbits, dogs, sheep, goats,15 and more
recently, alpacas have been employed.68,69 Each animal model has dis-
tinct advantages and disadvantages, and therefore the choice of the
animal model depends on the research question posed. It is important
to note that no animal model can reproduce the exact nutritional sta-
tus, biology, anatomy, and biomechanics of the human spine. Animal
models differ considerably; there are even pronounced differences
between animal breeds. It is evident that the difference in clinical rep-
resentation of IVD-related disease may strongly be related to the
genetic background of the breeds (reviewed for dogs70). Similarly, also
in humans, genetics play an important role as there have been “risk-
genes” identified in this sense. Although several predisposing genes
have been reported (eg, aggrecan, collagen type I and XI, matrix
metalloproteinase-2, -3 and -9, cartilage intermediate layer protein,
Interleukin-1 and -6), only the association of vitamin D receptor (VDR)
and collagen type IX (COL9A2) with IVD disease has been verified in
different ethnic populations.71,72 To our knowledge, no research has
yet been performed on the IVD of VDR null or vitamin D-deficient
animals. Collagen type IX deficient mice, show early developmental,
structural, and biomechanical alterations in their vertebral bodies and
IVDs, causing severe degenerative changes in the aging spine.73 Most
identified genes associated with LBP due to IVD degeneration code
for proteins affecting ECM integrity, responsible for mechanical prop-
erties of the IVD. Thus far, animal studies on the genetics of IVD dis-
ease use mice.74–76 Although far less well researched, also in larger
animal models employed for in vivo studies, genetics can play an
important role.77 Therefore, researchers need to consider this when
choosing a suitable animal model.
Differences in IVDs between human and animal species include
anatomical (size, shape), biomechanical, biochemical, aging/degenera-
tion, nutritional, cellular, and loading variations as reviewed by Alini
et al.15 The difference in IVD size affects the type and number of
readout parameters that can be measured: small IVDs cannot be used
to evaluate multiple parameters and assay detection limits coincide
with small samples. Also, limitations in relevant volume of therapeutics
relative to tissue constructs are encountered.78 Although for large ani-
mal models this is not a specific issue, safe injection volumes and pres-
sure should be determined to avoid injection-induced accelerated
degeneration.79 In this respect, IVD organ cultures are useful for injec-
tion volume and extrusion testing before animal models are employed.
FIGURE 4 Results generated from a literature search for papers published over the last 20 years (1997-2017) on regenerative treatments for the
intervertebral disc in animal models. Hundred and twelve papers in total were reviewed and the outcome measures were separated into
histological, macroscopic, radiological, biochemical, mechanical, and pain assessment. (A) Demonstrates the percentage (%) of these published
papers that each of the different outcome measures were used in. (B) Demonstrates the number of different outcome measurements used within
these publications
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By using this approach, previous studies have demonstrated that no
adverse effects were observed due to the intradiscal injections them-
selves, indicating that small volumes can be safely injected (rat:
1-8 μL,80–82 rabbit: 10-20 μL,83–88 dog: 40-50 μL,67,89,90 sheep:
0.2-1.0 mL91,92). We recommend injecting these IVD treatments only
through the AF. Recent work has shown that the transpedicular
approach, proposed as alternative delivery route for IVD
regeneration,93 induced severe damage to the end plates and may
lead to neurological impairment and leakage of injected material.94
Besides size, the second difference between animal models is that
in most animals, degeneration needs to be induced, since this is not a
spontaneously occurring phenomenon. Exceptions are the sand
rat95,96 and the dog,70 in which IVD degeneration occurs spontane-
ously with aging and is, at least in the dog, a clinical entity.97 In small
animals, IVD degeneration can be induced by genetic
modification,74,76,98 partial NP removal,99 IVD puncture,100–102 com-
pression103,104 (eg, tail-looping105) and even whole body vibration.106
In large animal models, IVD degeneration can be induced by creating
annular defects,88,107,108 partial NP removal91,109,110, and enzymatic
NP digestion.111 A recently proposed option to induce NP damage is
the use of laser technology,111 which induced more progressive and
less pronounced IVD degeneration than enzymatic NP digestion.
Researchers should thoroughly consider which IVD degeneration
method to use, dependent on the research question(s), outcome
parameters. and treatment candidate.
The third difference between species is the main cell type in the
NP. Humans lose their notochordal cells (NCs) during childhood,112
whereas aging mice,113 (sand) rats,96,114 rabbits,115 and nonchondro-
dystrophic (NCD) dogs70 typically still have NCs in their NP. In con-
trast, chondrodystrophic (CD) dogs,70 sheep,116 and goats117 lose
their NCs early in life and therefore more closely resemble humans in
this respect. Noteworthy, since in several animal species the main NP
cell type changes with aging, the age of the experimental animals
should be chosen cautiously.
In addition to interspecies differences, all common animal models
are quadrupeds. The biomechanical forces exerted on the human IVD
are often thought to be uniquely determined by the predominantly
upright stature and bipedal locomotion of humans, and are therefore
thought to be different to those found within in quadrupedal animal
models. However, because of its segmental unstable nature, all spines
rely on considerable tensile forces in intersegmental muscles (active)
and ligaments (passive) to generate compressive loading on the ante-
rior spinal column for sufficient stabilization. In quadrupeds, these
anterior column compressive forces may in fact be higher than those
in humans as demonstrated by the higher degree of longitudinal verte-
bral trabecular alignment and denser trabecular bone.15,118 Of course,
in addition to compressive loads, spinal segments must rotate in three
degrees-of-freedom, and it is understandable to imagine that humans
may require different motions from their spine than quadrupeds.
However, when comparing the passive resistance to bending, Wilke
et al found that the range-of-motion of sheep spinal segments for all
load directions was qualitatively similar to that of humans.119 Never-
theless, when (regenerative) treatment candidates are tested in animal
models in vivo, biomechanical testing in comparison to proper controls
is recommended.
Altogether, it is extremely important to choose an appropriate
animal model to test a (regenerative) treatment. The authors give rec-
ommendations in Table 2. Although small animals do not adequately
represent humans considering the fact that IVD degeneration needs
to be induced and the presence of NCs, they can be valuable for
answering developmental questions, for example, by using genetic
modification. Notably, a few ongoing clinical trials received an investi-
gational new drug (IND) only based on small animal models. It remains
to be determined whether this development in the regulatory scene is
in the benefit of the patient. Two examples supporting this concept
are recombinant human (rh) BMP7 and GDF5. Both were approved
for intradiscal application based on small animal models. While a clini-
cal trial Phase I/II was initiated for rhBMP7, it was never completed
and results remain elusive. Furthermore, several clinical trials explored
the efficacy of rhGDF-5 and the results were inconclusive. Receiving
an IND-based on small animal models may make product development
more affordable and shorten the time to market, but small animal
models may insufficiently predict efficacy in man.
When combining IVD size and NP cell type, sheep and goats more
closely resemble the human situation, but IVD degeneration also
needs to be induced. The question remains how adequately animal
models with induced IVD degeneration represent the cellular changes
which occur during natural degeneration in humans. Therefore, NCD
or CD dogs may more accurately resemble human IVD degeneration
where degeneration is spontaneous.120 Over the past few years, both
human and veterinary medicine have recognized the importance of
the “One Medicine” concept: bringing together human and animal
TABLE 2 Recommendations for the use of in vivo animal models
Mouse Rat Rabbit Sheep Goat Alpaca CD dog NCD dog
Cell type (CLC) in NP − − − ++ ++ ND ++ −
IVD size − − − + + + − +
Spontaneous IVD degeneration − − − − − − ++* ++*
Useful for fundamental/safety studies ++ ++ ++ − − − − −
Useful for translational/efficacy studies (−) (−) (−) + + + ++ ++
Expenses for animal experiments ++ ++ ++ + + + − −
Abbreviations: CD, chondrodystrophic; CLC, chondrocyte-like NP cell; NP, nucleus pulposus; IVD, intervertebral disc; NCD, nonchondrodystrophic. ++:
Best suitable animal model for this specific purpose. +: Suitable animal model for this specific purpose. −: Less suitable animal model for this specific pur-
pose. (−): Although the authors consider these species less suitable for this purpose, recent clinical trials (efficacy studies) did not require large animal stud-
ies. ND: not determined. *: CD dog breeds typically develop IVD disease at relatively young age. NCD dog breeds can also develop IVD disease, but at an
older age, mostly due to trauma or “wear and tear”. In the other species, IVD degeneration needs to be induced artificially.
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health for new medical solutions, advantageous for humans as well as
animals. An important issue of translating treatment strategies into
preclinical animal models is the ethics of placebo treatment.121
Evidence-based placebo treatment increases the scientific validity, but
can in the case of an intradiscal sham injection pose risks and/or can
lead to reluctance by the owners of the animals. Offering the option
to provide the treatment to the patients that had previously received
the placebo may increase the number of study participants.
A downside of using large animal models are the ethics and high
costs (purchase and housing, multiple costly outcome parameters).
Altogether, this often leads to the use of a minimal number of large
animals included, impairing the power of the study. Furthermore, an
issue concerning all species is the absence of histological scoring sys-
tems. To our knowledge, this has only been developed for mice122
and dogs.123 In terms of imaging, large animal models have rather sim-
ilar possibilities as humans with LBP: radiography, fluoroscopy, discog-
raphy, computer tomography (CT), and magnetic resonance imaging
(MRI).67,90,124,125 However, there are some drawbacks. For instance,
quantitative MRI (eg, T1rho and T2 mapping) has been validated for
human IVD degeneration,126,127 but not for animals. Therefore, this
needs to be validated for other species, as well as how the spinal phe-
notypes present in animal models relate to human pathology to
improve translation. Another major concern regarding MRI analysis is
that there is a need for validation of regenerative process, since quan-
titative MRI has specifically been validated for IVD degeneration, but
not for regeneration, which does not necessarily follow an identical
reverse process. To this end, the recently identified correlation
between IVD degeneration, modic changes and back pain128,129 indi-
cates that in animal models too these entities need to be explored and
properly characterized to fully cover the whole spectrum of spine
pathology related to IVD degeneration. Lastly, long-term animal stud-
ies are lacking, but must be performed to demonstrate long-term
safety and efficacy in clinically relevant animal models and detect
pathological features that only develop after a long time period, such
as tumorgenicity, before treatments are translated to human clinical
trials. Regardless the approach, even if efficacy is demonstrated in a
large animal model, it does not necessarily guarantee efficacy in the
human patient. Considering the most recent developments regarding
regulation and ethics concerning animal modeling, further develop-
ments in the preclinical track need to focus on implementation of the
3Rs principles, where replacement and considerable reduction of ani-
mal experiments needs to be achieved with sophisticated alternatives
employing bioreactor technology mimicking the biology and biome-
chanics of the degenerative disc niche.
5 | REGULATION
Regulatory pathways for the Food and Drug Administration (FDA),
and Medicines and Healthcare products Regulatory Agency approval,
will depend on the therapeutic under investigation and whether it is
defined as a drug, biologic or device. When considering the well-
defined regulatory pathways for drugs, it is estimated that the average
length of time from discovery to clinical application is approximately
12 to 15 years with an estimated cost of $800 million.130 In contrast,
the regulatory pathways for biological therapeutic approaches are
often more complex and time consuming. The FDA have established
that biological drugs include blood-derived products, vaccines, in vivo
diagnostic allogenic products, immunoglobulin products, protein prod-
ucts and products containing cells or microorganisms.131 Given the
unique nature of biological therapeutics, the preclinical tests per-
formed to evaluate the safety, purity, potency and efficacy of the
therapeutic will often be specific to the biological therapeutic under
investigation. It is therefore recommended that researchers have con-
tact with their local regulatory authorities early on in the preclinical
experimental design process to ensure that the necessary experiments
are being performed in line with the requirements for an IND applica-
tion and premarket approval (biologics license application). Consider-
ation, early on during preclinical investigations, should also be given to
the manufacturing processes of the therapeutic. In comparison to
well-characterized synthetic small molecule drugs, regulatory authori-
ties will often require additional clinical studies to demonstrate the
identity, safety, purity, potency, and efficacy of the biologic following
manufacturing processes.132
Currently, there is an increasing research interest for the use of
implantable biomaterial scaffolds to replace tissues of the IVD as a
treatment strategy for LBP.133,134 Where the biomaterial scaffold is
delivered without cells or biological factors it will likely be classified as
an implantable medical device, which are typically subject to the regu-
latory requirements of class III medical devices (90/385/EEC).135
Again, it is essential that regulatory considerations are thought of
early on, even while the initial in vitro investigations are being per-
formed; this is because certain long-term surveillance studies may be
required for regulatory approval, for example, long-term degradation
and materials characterization studies in accordance with the
ISO10993 standards.136 Where cells are either incorporated within
biomaterials scaffolds or used individually for regenerative purposes,
the therapy will likely be classified as an Advanced Therapy Medicinal
Product.137 However, the classification of systems is different within
each regulatory authority and is beyond the scope of this review to
advise specific regulatory guidelines. Investigators are encouraged to
contact their local regulatory bodies for advice as early as possible in
the developmental pipeline, to enable appropriate investigations to be
incorporated into development.
6 | CLINICAL TRIAL DESIGN
Translating a potential product with great preclinical data to clinical
reality, that is, from the bench to bedside, requires numerous steps.
For a therapeutic agent that will be injected into the IVD under image
guidance as a single dose, the pathway will be that for a new drug
application, biological agent, medical device, or advanced therapy
medical product. While the regulatory nuances can differ from one
regime to another, some principles remain the same. Here, we
describe numerous steps, documents, principles, and three-lettered
acronyms involved in completing the clinical translational work for
regenerative therapies for the IVD (Figure 5). On identification of a
suitable target, completion of proof of concept work, assuring a high
quality Chemical and Manufacturing Control when needed,
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confirmation of preclinical toxicological work on the final product that
will be used in clinical trials, with or without the requirement that the
final product is made using Good Manufacturing Practices. A team
with experience in early commercialization or clinical translation must
be involved.
An Investigator Brochure is the first step. This document summa-
rizes the history of the product development, characterization of the
active pharmacological/biological ingredient, medical device or ATMP,
mechanism of actions, all preclinical work and toxicological profiles
(Table 3; list of toxicological work) and any functional pain studies per-
formed. An indication for use (IFU) has to be stated clearly. It is impor-
tant that all preclinical and proof of concept work is consistent and
appropriate with this IFU.
The IFU becomes the basis of developing a Clinical Trial Protocol
(CTP). This activity requires the input of clinicians who understand the
Good Clinical Practice (GCP) for Trials and the Helsinki declaration.
Trials are to be conducted on sites that are GCP compliant, as deter-
mined by the clinical trial sponsor from the initiation to completion of
the study. The key elements of the CTP are: clear identification of the
inclusion and exclusion criteria, clearly defined outcome measures and
validation of the tools for clinical outcomes, a time table for what will
be measured when, establishment of a Data Safety & Monitoring
Board that can stop a trial in the event of a Serious Adverse Event,
and a detailed Subject Information Sheet/Document. For patients
undergoing a LBP study, each clinical trial protocol will be different,
however, the minimum expectation for outcome tools will include a
score for back pain, a disability measuring tool and a quality of life
instrument (Table 4). Patient Reported Outcome Measures while gen-
erally accepted, are being questioned now in favor of subjectively
FIGURE 5 A road map of the pathway to clinical success of a potential intradiscal therapeutic agent. While each stage has hurdles of its own,
comfort with acronyms and language around various steps and documentations needed is a good first step in resolving those hurdles. All activities
may cumulatively take anywhere between 12 to 15 years. CMC, chemical and manufacturing control; GMP, good manufacturing practices; IND,
investigational new drug; IFU, indication for use; IRB, institutional review board or ethics committees
TABLE 3 Toxicological and analytical work that may be required for
investigational new drug (IND) application
Type of study Model
Pharmacokinetics
Intramuscular pharmacokinetics Rat
Six-month single dose safety study Rat
Toxicology
Pyrogen test Rabbit
CNS safety profile Rodents
Blood fibrinogen consumption
test, platelet activation,
complement activation test,
hemolytic activity test
Human blood in vitro
Cardiovascular and pulmonary
safety
Rodents
Intramuscular bone or tissue
induction
Rodents
Effects on cell phenotype,
metabolic activity, binding/
affinity studies
In vitro depending on
active ingredient (described
above in preclinical studies)
Bioanalytical
Dosing solution/delivery agent
method development and
validation
In vitro
Plasma assay development and
validation
In vitro
The principles of understanding the pharmacodynamics and pharmacoki-
netics along with toxicological profile of the agent while being able to
quantify the drug, its metabolite have to be demonstrated for other
advanced therapies (including cell therapies), the toxicological and analyti-
cal work required is derived from the principles for drugs as listed.
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quantifiable measures with the advent of wearable devices and poten-
tially using biomarkers for disc degeneration.138
Radiological outcomes will be expected too, where the minimum
will be a disc height measurement on a standing lateral X-ray in neu-
tral position. While (quantitative) MRI provides information on the
degenerative stage of the IVD at the initiation of the study, the role of
clinical MRI as outcome measures are uncertain and may not serve
practical utility during a clinical trial. However, including MRI as a sec-
ondary read out parameter will assist follow up of the degenerative
state of the treated disc and demonstrate the development or lack of
additional pathologies, for example, modic changes. The role of end-
plate changes cannot be discounted but there is lack of consensus
among researchers and clinicians as to their importance or predictive
role in LBP. T1rho MRI mapping has been recently proposed as a
marker for painful discs.139 However, lack of extensive clinical use and
inadequate extensive validation of this imaging modality requires
more work. Secondary outcome measures may include use of supple-
mentary therapy and ability to work. Adverse events (AEs) are moni-
tored throughout the trial and serious adverse events would include
death, paralysis, infection and un-remittent exacerbation of pain.
In the context of the United States Food and Drug Authority, an
intradiscal therapeutic agent will be assessed as a drug product by the
Center for Drugs Research and Development (Figure 6). It is expected
that a New Drug Application (NDA) has to be lodged, towards which
the trial has to be conducted under an IND. This will require a safety
combined with dosage study as a Phase II clinical trial followed by an
efficacy Phase III trial, where a double blinded randomization (patient
and physicians including care team do not know who received the
drug till final data analysis) using a placebo arm to compare the experi-
mental therapeutic agent. Since no objective outcome measures are
available, the subjectivity of clinical symptoms is high in patients with
IVD disease. Therefore, determining the effects of placebo treatment
(eg, sham intradiscal injection) is preferable for scientific validity. Pla-
cebo treatment creates an ethical dilemma between maximizing the
scientific value of the study and minimizing risk to participants. The
ethical acceptability of placebo treatment is therefore mainly affected
by the associated procedure risks for the relatively healthy patients
with IVD disease, which often do not suffer from any comorbid-
ities.121 In both Phase II and III trails, data for safety has to be compul-
sorily obtained and preliminary efficacy can be tested in Phase
II. Whether a regulatory agency will accept another expedient clinical
trial model like a single arm study without a control will be dependent
on the ability of the sponsor to demonstrate compelling socio-
economic reasons or “orphan-disease” status for their indication. Fur-
thermore, varying dose studies, multiple disc levels treatment or a
repeat injection study should best be addressed after market approval
for the drug for one level and one dose; as incorporating these ques-
tions in a regulatory study will not only make the trial unwieldy, but
also add un-sustainable cost and time. Such further studies can be
investigator-initiated with or without regulatory oversight.
A complete statistical plan and data management plan are essen-
tial. The trial has to be listed at clinicaltrials.gov. Data from the IND
(in case the therapy is a protein or a drug) has to be submitted for a
NDA which requires multiple and stringent regulatory reviews that
may include panels consisting of lay persons and experts. Other regu-
latory regimes have similar or slight variations. In case a scaffold is
classified as a device an Investigational Device Exemption (IDE) study
submission followed by a Pre Market Approval (PMA) will be needed.
The IDE may require a pilot, a pivotal or a comprehensive study based
on what is being evaluated and in consultation with the FDA utilizing
their pre-submission process. More importantly, regulatory harmoni-
zation between various countries can help to speed up regulatory
FIGURE 6 Drug approval process from bench to bedside. Phase I
may not be needed for intradiscal therapies. Direct entry to Phase II
or Phase III will be suitable and appropriate for therapies that have a
human physiological basis or derivation rather than a small molecule,
drug or carrier that may be novel and not a known carrier. FDA, Food
and Drug Administration; IND, investigational new drug application
TABLE 4 Minimum outcome measures for a low back pain study
Minimum outcome
measures Example of scoring system/measurement
Pain VAS, NRS
Disability ODI, Roland Morris
Quality of life SF36, EQ5
Radiological DHI, MRI scans (if possible T1rho mapping)
Abbreviations: DHI, disc height index; EQ5, European quality (of life)
5 questions; MRI, magnetic resonance imaging; NRS, numeric rating scale;
ODI, Oswestry disability index; SF36, 36-item short form health survey;
VAS, visual analog scale.
A clinical trial protocol has to consist of subjective (patient reported) and
objective (investigator determined) outcome tools.
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TABLE 5 Intradiscal therapies that have undergone or are undergoing clinical trials
Intradiscal therapies under an IND or with a clinical trial number or published
Active agent Sponsor name
Clinical trial number/
IND/reference Status/outcome
Allogeneic discogenic cells DiscGenics Inc. NCT03347708 FDA allowance of IND to commence clinical study
(October 2017). Currently recruiting.
Autologous disc cells TETEC; NOVOCART NCT01640457 Phase I/II (n = 120); ongoing
Allogeneic juvenile chondrocytes NuQu, ISTO
Technologies Inc.
NCT01771471 Phase II enrolment completed (n = 44); final results
expected in 2014. Current status: terminated
(change in clinical strategy)
Allogeneic mesenchymal
precursor cells (MPC-06-ID)
[STRO enriched]
Mesoblast Ltd. • NCT01290367
• NCT02412735
• http://mesoblast.com/
clinical-trial-results/
mpc-06-id-phase-2
• Phase II (n = 100): significantly greater pain
reduction (VAS, ODI, opioid use), but large placebo
effect. IVD MRI changes are missing.
• Phase III (n = 360): ongoing. Cells with hyaluronic
acid vs placebo
Allogeneic bone marrow-derived
mesenchymal stromal cells
Red de Terapia
Celular
NCT01860417 Phase II (n = 25): results not published
Allogeneic bone marrow-
derived mesenchymal
stromal cells
Noriega et al (2017)140 Phase I (n = 24) showed safety. 40% responders
Autologous adipose-derived
mesenchymal stromal cells
Kumar et al (2017)141 Phase I (n = 10) showed safety. VAS and ODI scores
significantly improved
Autologous bone marrow
concentrate cells
Pettine et al (2015)142 Pilot study (n = 26): ODI and VAS scores reduced.
Eight patients improved by one modified Pfirrmann
grade
Placental tissue extract
(BioDGenesis)
Semmes-Murphey
Foundation
NCT02379689 Phase I/II (n = 30): results unknown
Recombinant human bone
morphogenetic protein-7
(rhBMP-7)
Stryker; Olympus
Biotech
Imai et al (2007)85,90 • Product available in Australia, Canada, Germany,
Italy and Spain for bone formation
• Development for intradiscal injection did not
progress beyond Phase II trials. In line with this,
later in vivo experimental work demonstrated the
absence of a regenerative effect and possible
adverse effects in Beagle dogs
Recombinant human
growth and differentiation
factor-5 (rhGDF-5)
DePuy Synthesis
Spine (J&J subsidiary)
• NCT01158924 (n = 40)
• NCT00813813 (n = 32)
• NCT01182337 (n = 31)
• NCT01124006 (n = 24)
All studies completed Phase II; inconclusive study
results
Fibrin BIOSTAT BIOLOGX • NCT00693784 (pilot study);
Yin et al (2014)143
• NCT01011816 (Phase III)
• Pilot study (n = 15) showed safety
• Phase III (n = 220) withdrawn because of lack of
efficacy
• Product on market for other indications including
surgical hemostasis
Methylene Blue • Peng et al (2010)
• Levi et al (2014)
• Kallewaard et al (2016)
• NTR2547 (NL)144–147
• Phase I (n = 40): preliminary
• Peng et al (2010) (n = 136): reduction in pain, ODI,
improved satisfaction rate
• Levi et al (2014) (n = 16): no clinical success
• Kallewaard et al (2016) (n = 15): 40% positive
responders
IL-6R mAB Sainoh et al (2017)148 Tocilizumab, Actemra, and RoActemra available on
market. Efficacy for back pain not known.
Platelet-rich plasma • NCT02983747 (Phase II)
• Monfett et al (2016)
(literature review)
• Tuakli-Wosornu et al (2016)
• Levi et al (2016)
• Akeda et al (2017)149–152
• Phase II (n = 112) completed, results are awaited.
• Tuakli-Wosornu et al (2016) (n = 47): improvements
in FRI, NRS, and patient satisfaction
• Levi et al (2016) (n = 22): after 6 months success
rate of 47% (eg, 50% improvement in VAS and 30%
decrease in ODI)
• Akeda et al (2017) (n = 14): VAS score improved,
MRI T2 values not changed
Glucocorticoid Hydro-cortancyl
(Predniso-lone)
• NCT00804531
• Nguyen et al (2017)153
Phase IV (n = 137): efficacy not clear
YH14618 Yuhan Corporation NCT02320019 • Peptide derived from biglycan, binds to TGFβ1 and
downregulates Smad1/5/8 signaling
• Phase II (n = 326) completed, results awaited
AMG0103 AnGes, Inc. NCT03263611 • Nuclear factor-κB Decoy oligodeoxynucleotide
THORPE ET AL. 11 of 18
approvals. Intradiscal therapies that have undergone or are undergo-
ing clinical trials are provided in Table 5. As one can deduce from the
table, there are several developed molecular or biological therapies
that have failed thus far to show efficacy, while other remain in the
race. The challenges and hurdles that still remain may have to do with
not only the harsh environment of the degenerative disc. Patient
stratification is an important consideration for achieving desirable out-
comes. Appropriate trials and identifying which patients will benefit
from which treatments is essential to determine the commissioning/
approvals of treatment regimes.
Funding the intradiscal treatment, will vary in different countries
where different medical funding models apply. In some countries
where health is mandated both by state and federal/central govern-
ment, there may be significant variation among states and different
payers. Concomitant with the challenges of reimbursement, extensive
physician and surgeon education has to be conducted to better under-
stand the indication, technique of delivery, mechanism of action,
potential side effects and appropriate follow up of the patients. “More
is not always better” as outlined by the well-known side effects of
off-label use and controversial indication of recombinant Bone Mor-
phogenetic Protein-2 (BMP-2) in spinal fusion.154 In this respect, cell
transplantation and growth factor dosing needs to take into consider-
ation the demanding disc mileau. Once approved, post-market surveil-
lance and other investigator-initiated studies will form the basis of
systematic reviews and meta-analysis that will lead to further fine-
tuning of indications and or dose regimes.
7 | INTELLECTUAL PROPERTY AND
COMMERCIAL SUPPORT
Intellectual property (IP) is a term that describes creations of the mind,
such as inventions; literary and artistic works; designs; and symbols,
names, and images used in commerce. It is divided into industrial
property and copyrights. IP protection allows the holder to exclude
others from interfering with or using the property right in specified
ways. The main forms of IP are patents, copyrights, trademarks, and
trade secrets.155 To obtain the grant of a patent, one must file a pat-
ent application at a patent office. It is important to file an application
as soon as possible, because after the filing date, disclosing to the
public no longer forms prior art and if a full patent application is
granted provides protection for 20 years from the earliest filing date
of the application, not from the date that the patent was granted.
The first stage in securing IP is to perform a patent search of data-
bases to find out if a patent has already been filed or granted that is
similar to your patent. A great place to start a preliminary patent
search is Google patents at https://patents.google.com. Other free
patent databases are patent lens https://www.lens.org/lens/bio,
DOepatents https://www.osti.gov/doepatents/about.jsp developed
by the US Department of Energy (DOE), USPTO (United States Patent
and Trademark Office) http://patft.uspto.gov and Espacenet https://
worldwide.espacenet.com/advancedSearch?locale=en_EP.
This is important because it is possible to spend considerable funds
preparing and filing an application when there is prior art that will pre-
vent a patent, or make the patent very narrow.156,157 Those individuals
within academic institutions will have a technology transfer office
(or equivalent) within their institution who will normally manage this
process and provide funding if deemed to have potential. Discussion
with the local technology transfer office as soon as inventors feel they
have something worth patenting is essential. Most technology transfer
offices will have their own experiences of patenting and commerciali-
zation who will work with inventors to collect initial patent searches.
The knowledge from these searches will help with accentuating both
the positive aspects of your invention and the differences that exist
over the prior art, leading to a stronger patent application.157
The next step is to file for a provisional patent application where
the filing date is recorded officially with the assistance of a patent
attorney and then within 12 months file a nonprovisional patent appli-
cation. If inventors fail to submit the full application within 12 months
of the provisional patent then this will automatically run out and any
protection is lost. While, typically inventors do a search after the filing
of the provisional patent application but before the filing of the non-
provisional patent application,158 it is advised to complete this prior to
filling the provisional. The reason not everyone chooses to do a patent
search first is because of the high cost of hiring a patent attorney.
Certainly, recording your invention as quickly as possible and getting
an early filing date has its advantages. However, the best course to
follow, if funds are available, is doing a patent search first before any
patent application is filed. By doing a patent search and receiving pro-
fessional help from a patent attorney you will be able to determine
whether it makes sense to move forward and what, if any, rights could
be possibly obtained. Furthermore, inventors will search the database
for themselves to be informed of the patent landscape so that they
can determine whether it even makes sense to start or continue a pro-
ject in a certain way and whether there may be some available space
that they could target.
Do not disclose your inventions until the provisional patent appli-
cation is on file as any public activity associated with the invention
such as telling others at conferences, in abstracts or as a publication
TABLE 5 (Continued)
Intradiscal therapies under an IND or with a clinical trial number or published
Active agent Sponsor name
Clinical trial number/
IND/reference Status/outcome
• Phase I (n = 24): recruiting
SM04690 Samumed LLC NCT03246399 • Small-molecule inhibitor of Wnt pathway
• Phase I (n = 18): recruiting
Abbreviations: FDA, Food and Drug Administration; FRI, functional rating index; IL-6 mAB, interleukin-6 monoclonal antibody; IND, investigational new
drug; IVD, intervertebral disc; ODI, Oswestry disability index; OUS, outside of the United States; MRI, magnetic resonance imaging; NRS, numeric rating
scale for pain; VAS, visual analog scale.
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negatively affects the patenting.155 This creates a conflict with acade-
mia in terms of putting students on a patentable project. After all,
many academics are going to need assistance from students in order
to bring their invention into being. However, students need publica-
tions, presentations, abstracts, etc. for their career, which are often
delayed by the patenting process.
Some governmental or private funding is only accessible once you
have a patent application on file. Typically, the research projects pro-
posed should not only be beneficial to health but also have a strong
focus on knowledge translation with clear milestones and decision
points. This is also a Catch-22, that is, easier to get funding with a pat-
ent, but need data for the patent, data is usually only possible with
funding. Furthermore, once the patent is filed the clock is ticking as
the patent is only enforceable for a limited time. This, particularly for
clinical therapies, means that protected time can run out before prod-
ucts reach the clinic.
A consideration of where to protect IP is also important, there are
many factors to consider before selecting which countries to apply for
patent rights.155,157 Among the key considerations are the available
budget, market opportunities, the time pressure that exist, the loca-
tion of suppliers and competitors. As a rule of thumb, the most com-
mon regions are the United States, Europe, China, Japan, India, Russia,
Brazil, South Korea, and Mexico, because they are large economies.
Other countries such as Canada, Australia, and South Africa and far
eastern economies, such as Thailand and Indonesia, should also be
considered. While patent law has been harmonized on an interna-
tional level, there are still differences between countries. Estimating
costs per country per year is challenging. Costs usually have an offi-
cial, an associate or attorney fee, a translation fee and a maintenance
fee in many countries. It is estimated that if one was to obtain a pat-
ent in each of the close to 200 countries that exist on the planet the
cost would be $2 000 000 for filing, issuance and maintaining the pat-
ent for its full term. The best strategy is to first get the US patent on
file, then file for a PCT which cost roughly about $5000 and buys you
an additional 18 months when you add from the date you file the US
patent application before going into other countries or jurisdictions.
There are five leading jurisdictions to file patents. The US patent, the
European patent office, and the Japan patent office are called the Tri-
lateral and they work closely together. Then there are the Chinese
and Korean jurisdictions. Thus 90% of patent applications are filed in
the Trilateral, China, and Korea. However, you have to make sure that
you have something that is economically worthwhile before going
international.
Financing a commercial operation is a difficult task for many aca-
demic IP owners, particularly with the added stress of working at a
University. In order to encourage commercialization of intellectual
property developed by universities or colleges, some types of support
and assistance are available. Where technology transfer offices exist,
early conversations are essential to gain university backing and sup-
port for patent applications and funding. Furthermore, there are often
government resources available and nongovernmental organizations
that provide support to technology and innovation entrepreneurs.
Gaining support for patenting may require development of a business
model at many institutions.
Ideas that are promising can start in universities and evolve into
highly profitable businesses. The development of a spin-out from the
university is challenging as most academics have no experience in
understanding what the customer needs, assessing the demands of
the market demand and raising money. Apart from being risky, a spin-
out requires time, effort, and funding. For research to be transformed
into a successful business, there are five steps namely, research, proof
of research market and technology, market and technology develop-
ment, product and business development and exit. Funding sources
depend on what step and can come from government, holding compa-
nies, venture capital, customers, industrial partners, banks, angels and
crowd funding to mention a few.
Recently, “incubators” have developed in the United States,
Europe, and Asia, where an inventor can have support during product
development. These incubators are set-up and supported by academic
institutions, governmental agencies, nonprofit foundations, and even
commercial entities with financial support coming from their respec-
tive sponsors. Similar to business incubators, these organizations pro-
vide not only infrastructure and resources to accelerate business
development but to translate the IP towards a commercial product.
This is often done in exchange for a share of or exclusive transferrable
license rights to the IP. As these incubators or engines can be highly
specific to the medical field and hold much specific expertise, they are
able to considerably accelerate the formation and maturation of spin-
outs in a successful manner. At the moment it can take millions of dol-
lars and on average 12 years to get from bench to patients depending
on the invention.
8 | DISCUSSION
Over the last two decades, there has been a vast amount of published
literature on the preclinical development of novel therapies for IVD
degeneration. However, to date we still do not have a therapy which
addresses this unmet clinical need. Through scientific research, the
IVD field has a greater understanding of the physiological and cata-
bolic environment of the degenerate niche and the biological impact
that it has on the cells and extracellular matrix. Research within the
community has also uncovered key differences in cell behavior and
phenotype with species and culture conditions. It is essential that this
scientific knowledge is incorporated into the preclinical design to
accelerate and improve translation of findings from preclinical devel-
opment to clinical studies. It is accepted that the culture conditions
used within preliminary proof of concept studies will depend on avail-
ability of resources and the research question being investigated.
However, at some point during the preclinical phase, novel therapies
should be investigated using human cells/tissues within culture condi-
tions that mimic those most closely seen within the degenerate
human IVD (Table 1). Utilizing human cells/tissues early within the
developmental pipeline will enable aspects such as patient variability
to be explored and will require multiple patient samples to be investi-
gated in vitro. These experiments will be the most clinically relevant
and thus reduce risk of failure within clinical studies. Standardized
approaches to preclinical investigations of novel therapies from 2D
culture to organ culture systems, which mimic the in vivo IVD
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(Figure 1), will aid comparison with competing therapeutics, so that
the best candidate therapies go forward to clinical testing and, thus,
improve the chances of progression to clinical use. The therapeutics
found to be most promising in the preclinical (in vitro/ex vivo) phase
still need to be tested in animals before they can enter human clinical
trials. As no single animal model will exactly match human IVD degen-
eration in all of its complex aspects, it is important to choose an
appropriate animal model, based on the most important research
questions and desired outcome parameters. Small animal (eg, rodent)
models are very useful for fundamental/safety studies, whereas the
more expensive large animal models are more suitable for transla-
tional/efficiency studies. In all animal models, however, the outcomes
should be determined objectively, for example, by randomization,
blinding, and quantitative scoring systems.
Scientists are often not well informed about the regulatory
pathway. Hence, they should contact their local regulatory authority
as early as possible to gain appropriate advice. To determine the
pathway, the therapeutic under investigation should be classified
which will define the preclinical work required for regulatory accep-
tance. As work proceeds, it must be fully documented in accordance
with GLP procedures and entered in a treatment strategy file so
that they can be submitted and reviewed as part of the regulatory
process.
To obtain meaningful results from a clinical trial, regardless of its
therapeutic success, applying regulatory knowledge, developing a
good design and thorough planning, with sufficient control throughout
the trial is essential. Investigator brochures, summarizing principal and
pertinent preclinical results, are important to inform the clinical trial
team. Clinical trial protocols must define IFU with strict and unambig-
uous inclusion and exclusion criteria to create a focused and uniform
patient population. Outcome measures must be well defined and vali-
dated across centers and their collection and management must be
controlled.
IP is an almost necessary component for bringing new therapeutic
agents to the clinic. Without it, commercialization is nearly impossible.
Hence researchers should be mindful of IP in their dissemination
activities. IP searches need to be performed early and prior to external
discussions. Provisional and patent applications can provide protec-
tion, but are not without substantial costs, and a business plan should
be developed as part of the IP strategy. For this purpose, discussions
with the institutional technology transfer office or patent agents
should be done early and are immensely helpful. For IP commercializa-
tion, licensing to established companies is one option but SMEs are
more attractive in terms of retaining control and involvement. For
SMEs, valuable developmental resources include governmental valori-
zation grants/loans and incubators/engines.
In conclusion, for successful translation of regenerative thera-
pies to clinic, it is essential to plan your pathway to clinic from the
outset, take advice early on regulatory and commercial aspects and
consider the required proof of concept experiments required to sat-
isfy regulatory approval for clinical trials. Do not delay too long,
otherwise any protection will run out, which makes commercial
interest difficult (and often this is the only way to fund expensive
clinical trials).
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